Fig. 20From: Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysisMeta-analysis of rash/skin toxicityBack to article page
Systematic Reviews